Skip links

Livdelzi® (seladelpar)

Full Name Livdelzi® (seladelpar)
Drug Livdelzi
Manufacturer Gilead Sciences, Inc.
Route of Administration Oral
Site of Care Home
Approved Indication Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA
Disease Primary Biliary Cholangitis (PBC)
Therapeutic Area Hepatology
Enrollment Form Link Enrollment Form
Phone Number 888-263-8004
Fax Number 877-846-0402
Product Website livdelzihcp.com/